Vivek Ramaswamy’s Enzyvant is hit with a CRL for manufacturing — delaying a new therapy for an ultra-rare killer
It was supposed to be Vivek Ramaswamy’s first drug approval, but the regenerative med company he set up to advance a new tissue-based approach to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
